Caplin Point Laboratories share price
NSE: CAPLIPOINTBSE: 524742Pharmaceuticals & BiotechnologySmall Cap
Caplin Point Laboratories Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1995 on BSE, Jun 2014 on NSE
Last close ₹2,352.40up ₹78.50 (3.45%)BSE ₹2,354.35
Share price at the NSE close on 27 Oct 2026. Previous close ₹2,273.90.
27 Oct: open ₹2,294.50, high ₹2,375.00, low ₹2,276.10
52-week range of traded prices to 27 Oct 2026
₹1,500.30Low, 30 Mar 2026₹2,990.00High, 24 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹17,881 Cr453rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.87
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.99
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.34%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 19.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 87,85041.3% delivered
About Caplin Point Laboratories
Caplin Point Laboratories Limited is a pharmaceutical company. It manufactures and markets finished formulations, manufactures active pharmaceutical ingredients, and carries out research and development and clinical research. Its business model mostly serves emerging markets of Latin America and Africa, and it has a growing presence in regulated markets such as the USA.
It offers more than 650 formulations across 36 therapeutic areas, including tablets, capsules, liquid orals, ointments, injectables and ophthalmic products. The group is organised by subsidiary. Caplin Steriles Limited makes injectable and ophthalmic products for regulated markets. Caplin One Labs Limited makes oncology formulations. Caplin Point Far East Limited, a wholly owned subsidiary in Hong Kong, holds the Latin American subsidiaries and consolidates the emerging market distribution network. Caplin Steriles USA Inc. is a subsidiary of Caplin Steriles Limited, and it reaches over 14,300 hospitals, pharmacies and clinics in the USA.
Manufacturing sites are at Suthukeny (Puducherry), Kakkalur (Chennai), Gummidipoondi (Chennai) and Visakhapatnam (Andhra Pradesh). Some products are made at approved outsourced sites in India and China. Products are registered in more than 55 countries.
It was incorporated in 1990. Its founder, C.C. Paarthipan, started a partnership venture in 1987 to make external ointments and creams. The company became a public limited company in 1993 and listed on the Indian stock exchanges in 1994. From 2000 it moved into Latin America and Francophone Africa. In 2022 it acquired an API plant in Visakhapatnam.
Written from the annual report for the year to Mar 2026, filed 3 Sep 2026 and the investor presentation.
Sources for 34 statements, each with its page
- It is a pharmaceutical company that manufactures and markets finished formulations, manufactures APIs, and does R&D and clinical research. Annual report, page 21
- It also manufactures active pharmaceutical ingredients and does research and clinical research. Annual report, page 21
- Its business model mostly serves emerging markets of Latin America and Africa. Annual report, page 21
- It has a growing presence in regulated markets such as the USA. Annual report, page 21
- It offers more than 650 formulations across 36 therapeutic areas. Annual report, page 31
- Products include tablets, capsules, liquid orals, ointments, injectables and ophthalmic products. Annual report, page 15
- Products include ophthalmic products. Annual report, page 15
- Tablets and capsules are among the products. Annual report, page 31
- Liquid orals are among the products. Annual report, page 31
- Caplin Steriles Limited makes injectable and ophthalmic products for regulated markets. Annual report, page 22
- Caplin Steriles Limited develops and manufactures injectables and ophthalmics for regulated markets. Annual report, page 22
- Caplin One Labs Limited makes oncology formulations. Annual report, page 22
- Caplin Point Far East Limited, Hong Kong, deals in emerging market distribution. Annual report, page 22
- It is the holding company of all the Latin American step-down subsidiaries and consolidates emerging market distribution. Annual report, page 22
- It consolidates the emerging market distribution network. Annual report, page 22
- Caplin Steriles USA Inc. is a subsidiary of Caplin Steriles Limited. Annual report, page 29
- Caplin Steriles Limited has a subsidiary (heading of the group structure list). Annual report, page 29
- The US business reaches over 14,300 hospitals, pharmacies and clinics. Annual report, page 11
- Manufacturing facilities are at Suthukeny (Puducherry), Kakkalur (Chennai), Gummidipoondi (Chennai) and Visakhapatnam (Andhra Pradesh). Annual report, page 21
- Kakkalur and Gummidipoondi in Chennai. Annual report, page 21
- Visakhapatnam in Andhra Pradesh. Annual report, page 21
- Some manufacturing is outsourced to approved sites in India and China. Annual report, page 21
- Outsourced sites are in India and China. Annual report, page 21
- Products are registered in more than 55 countries. Annual report, page 32
- It was incorporated in 1990. Annual report, page 62
- The founder is C.C. Paarthipan. Annual report, page 23
- The venture started as a partnership in 1987. Annual report, page 23
- The venture started in 1987 to make external ointments and creams. Annual report, page 23
- It became a public limited company in 1993. Annual report, page 23
- The change to a public company was in 1993 and it was listed in Indian stock exchange. Annual report, page 23
- It listed with its IPO in 1994. Annual report, page 23
- From 2000 it moved into Latin America and Francophone Africa. Annual report, page 23
- The move was from the year 2000. Annual report, page 23
- In 2022 it acquired an API plant in Vizag (Visakhapatnam). Annual report, page 25
Results
Consolidated; ₹ crore.Caplin Point Laboratories quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +15.0%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +17.7%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹610 Crup 1.70%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹179 Crup 3.59%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 29.3%
Revenue by quarter
Peak revenue ₹610 Cr, quarter to Jun 2026; lowest ₹483 Cr, quarter to Sep 2024
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 483 | 493 | 502 | 510 | 534 | 543 | 600 | 610 |
| Net profit | 131 | 140 | 145 | 151 | 160 | 166 | 173 | 179 |
| Net margin | 27.1% | 28.4% | 28.9% | 29.5% | 30.0% | 30.6% | 28.8% | 29.3% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹2,187 Crup 12.89%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹650 Crup 20.08%
- Net margin
- 29.7%
Revenue by year
Peak revenue ₹2,187 Cr, year to Mar 2026; lowest ₹405 Cr, year to Mar 2017
Net profit by year, a loss in red
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 405 | 540 | 649 | 863 | 1,061 | 1,269 | 1,467 | 1,694 | 1,937 | 2,187 |
| Net profit | 96 | 145 | 177 | 215 | 251 | 308 | 377 | 461 | 541 | 650 |
| Net margin | 23.7% | 26.8% | 27.2% | 24.9% | 23.7% | 24.3% | 25.7% | 27.2% | 27.9% | 29.7% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- Rest of the WorldRest of the World, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹1,734 Crup 9.53%79.3%
- USAUSA, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹453 Crup 27.89%20.7%
The pill is the change in revenue on the year before; the share is of all the businesses together.
Valuation
Today, against the company's own history.Caplin Point Laboratories PE ratio and valuation
Price to earnings
At or below today's level on 68% of 2,478 trading days over the last 10 years.
LowestHighest
Its median21.66Industry median28.51
Price to book
At or below today's level on 63% of 1,882 trading days since Nov 2018.
LowestHighest
Its median4.58Industry median2.94
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 45% of 2,468 trading days over the last 10 years.
LowestHighest
Its median0.35%Industry median0.50%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −24.2% | +19.5% | −37.1% | 0.5% |
| 3 years | +36.6% | +19.4% | +14.1% | 0.4% |
| 5 years | +30.6% | +21.4% | +7.2% | 0.5% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual fund holdings
64 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 49 of the 54 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.All 64 funds holding Caplin Point Laboratories
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 1
- AddedAdded. Funds that held more shares than at the end of the month before.
- 24
- CutCut. Funds that held fewer shares than at the end of the month before.
- 30
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 9
| Fund | |||
|---|---|---|---|
 UTI Small Cap FundUTI Mutual Fund | 3,60,882 | 1.87% | ₹98.0 Cr |
| UTI Large & Mid Cap FundUTI Mutual Fund | 2,48,238 | 1.08% | ₹67.4 Cr |
| UTI Aggressive Hybrid FundUTI Mutual Fund | 1,91,227 | 0.80% | ₹51.9 Cr |
| UTI Healthcare FundUTI Mutual Fund | 1,59,030 | 3.02% | ₹43.2 Cr |
| UTI Retirement FundUTI Mutual Fund | 79,628 | 0.47% | ₹21.6 Cr |
 Nippon India Nifty Smallcap 250 Index FundNippon India Mutual Fund | 31,032 | 0.24% | ₹8.43 Cr |
 Mirae Asset Nifty Smallcap 250 Momentum Quality 100 ETFMirae Asset Mutual Fund | 24,442 | 0.71% | ₹6.64 Cr |
 HDFC Nifty Smallcap 250 ETFHDFC Mutual Fund | 24,355 | 0.24% | ₹6.62 Cr |
 Quantum Small Cap FundQuantum Mutual Fund | 16,572 | 1.72% | ₹4.50 Cr |
 SBI Nifty Smallcap 250 Index FundSBI Mutual Fund | 15,764 | 0.24% | ₹4.28 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 28 Oct 2025.Caplin Point Laboratories insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Others: no market trade · 1 pledge filing of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Caplin Point Laboratories competitors and peers
Pharmaceuticals, 216 listed companies, priced on 27 Oct 2026. The table lists the 8 companies closest to Caplin Point Laboratories in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Neuland LaboratoriesNEULANDLAB | 24,781 | 49.78 | 13.22 | +78.3% | +182.6% | 29.3% | 32.1% | 0.18% |
 Granules IndiaGRANULES | 22,656 | 34.21 | – | +24.8% | +38.1% | 15.1% | 15.1% | 0.21% |
 Cohance LifesciencesCOHANCE | 18,336 | 172.61 | 4.69 | +41.2% | −58.5% | 3.8% | 3.0% | 0.00% |
 Onesource Specialty PharmaONESOURCE | 18,231 | – | 3.08 | +27.2% | – | −0.8% | 0.8% | 0.00% |
 Shilpa MedicareSHILPAMED | 17,694 | 59.51 | 6.83 | +27.9% | +167.6% | 12.0% | 10.9% | 0.07% |
 PfizerPFIZER | 16,971 | 23.09 | 4.04 | +10.7% | −9.1% | 17.5% | 21.0% | 2.02% |
 Eris LifesciencesERIS | 16,626 | 23.50 | 4.01 | +11.1% | +70.2% | 19.6% | 13.4% | 0.60% |
 Alivus Life SciencesALIVUS | 16,496 | 27.35 | 4.95 | +7.9% | +21.7% | 19.6% | 22.7% | 0.37% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Caplin Point Laboratories dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹8.00 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 18 Sep 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹4.00 |
| 29 May 2026 | Interim | ₹4.00 |
| 12 Sep 2025 | Final | ₹3.00 |
| 30 May 2025 | Interim | ₹3.00 |
| 23 Sep 2024 | Final | ₹2.50 |
| 31 May 2024 | Interim | ₹2.50 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Caplin Point Laboratories announcements
Sep 2026
25 Sep · Meeting
24 Sep · Legal
The exchange asked on 24 Sep 2026
4 Sep · Updates
3 Sep · Updates
Caplin Point Laboratories share price by year
Each calendar year to 2025.Caplin Point Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,838.10 | −26.5% | 2,583.25 | 1,713.80 |
| 2024 | 2,500.65 | +84.4% | 2,600.15 | 1,240.40 |
| 2023 | 1,356.15 | +90.1% | 1,421.10 | 584.15 |
| 2022 | 713.30 | −16.9% | 872.45 | 633.90 |
| 2021 | 858.20 | +69.5% | 956.00 | 403.45 |
| 2020 | 506.40 | +68.3% | 629.85 | 193.05 |
| 2019 | 300.85 | −21.2% | 454.60 | 288.25 |
| 2018 | 382.00 | −39.5% | 676.95 | 360.70 |
| 2017 | 631.45 | +84.0% | 758.55 | 335.60 |
| 2016 | 343.15 | +21.6% | 404.35 | 182.73 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 26 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 26 Oct 2026 | 2,220.00 | 2,306.40 | 2,208.90 | 2,273.90 | 2,263.50 | 66,506 | 36.5% |
| 23 Oct 2026 | 2,249.10 | 2,265.00 | 2,194.50 | 2,222.00 | 2,220.45 | 76,904 | 47.0% |
| 22 Oct 2026 | 2,197.60 | 2,263.00 | 2,176.20 | 2,249.10 | 2,227.37 | 73,971 | 43.9% |
| 21 Oct 2026 | 2,263.80 | 2,274.10 | 2,210.00 | 2,221.60 | 2,238.58 | 81,831 | 49.3% |
| 19 Oct 2026 | 2,301.30 | 2,322.10 | 2,255.00 | 2,258.80 | 2,284.01 | 70,397 | 45.0% |
| 16 Oct 2026 | 2,324.90 | 2,335.90 | 2,291.00 | 2,301.30 | 2,312.23 | 64,351 | 49.1% |
| 15 Oct 2026 | 2,338.20 | 2,361.90 | 2,248.10 | 2,301.80 | 2,311.32 | 1,32,807 | 42.8% |
| 14 Oct 2026 | 2,375.00 | 2,409.00 | 2,321.00 | 2,338.20 | 2,351.33 | 1,08,532 | 38.5% |
| 13 Oct 2026 | 2,419.80 | 2,425.60 | 2,325.20 | 2,361.60 | 2,358.80 | 1,67,353 | 43.5% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 19 Oct 2016 | Split | 0.2000 | Each share became 5. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- NSE symbol
- CAPLIPOINT
- BSE code
- 524742
- ISIN
- INE475E01026
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.caplinpoint.net
- CIN
- L24231TN1990PLC019053
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1990
- Registered office
- Ashvich Towers, 3rd Floor, No.3 Developed Plots Industrial Estates, Perungudi, Chennai 600096, Tamil Nadu
- Share registrar
- Integrated Registry Management Services Pvt. Ltd (Integrated Enterprises (India) Ltd)
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 500, BSE 500, Nifty Smallcap 250, BSE 250 SmallCap Index, BSE SmallCap, Nifty Total Market